Download Files:
Gunagratinib
$780 – $6,400
Products Details
Product Description
– Gunagratinib (ICP-192) is a low toxicity and orally active pan-FGFR (fibroblast growth factor receptors) inhibitor that potently and selectively inhibits FGFR activities irreversibly by covalent binding. Gunagratinib can be used for the research of cancer[1]. Gunagratinib is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
Web ID
– HY-132817
Storage Temperature
– 4°C (Powder, sealed storage, away from moisture and light)
Shipping
– Room Temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C22H25N5O4
References
– [1]Guo Ye, et al. Phase I result of ICP-192 (gunagratinib), a highly selective irreversible FGFR inhibitor, in patients with advanced solid tumors harboring FGFR pathway alterations. Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021) 4092-4092.
CAS Number
– 2211082-53-8
Molecular Weight
– 423.47
Compound Purity
– 99.36
SMILES
– CNC1=C(C(N)=O)C(C#CC2=CC(OC)=CC(OC)=C2)=NN1[C@]3([H])CN(CC3)C(C=C)=O
Clinical Information
– Phase 2
Research Area
– Cancer
Solubility
– DMSO : 100 mg/mL (ultrasonic)
Target
– FGFR
Isoform
– FGFR
Pathway
– Protein Tyrosine Kinase/RTK
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
